U.S. Supreme Court Won’t Review $124M Penalty For Risperdal Marketing

Mealey's (January 12, 2016, 8:46 AM EST) -- WASHINGTON, D.C. — The U.S. Supreme Court on Jan. 11 declined to review a $124 million consumer law civil penalty imposed by South Carolina against the Ortho-McNeil-Janssen Pharmaceuticals Inc. division of Johnson & Johnson for failing to disclose the risks and side effects of the atypical antipsychotic Risperdal (Ortho-McNeil-Janssen Pharmaceuticals, Inc., et al. v. South Carolina, ex rel., Alan Wilson, No. 15-600, U.S. Sup.).

In 2011, a South Carolina state court jury found that Janssen violated the South Carolina Unfair Trade Practices Act. Assessing the defendant...
To view the full article, register now.